Dynacure Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 29

Employees

  • Latest Deal Type
  • M&A

Dynacure General Information

Description

Operator of a clinical-stage drug development company created to improve the lives of patients with rare and orphan diseases. The company is developing an investigational antisense product candidate designed to reduce the expression of dynamin two protein for the treatment of myotubular and centronuclear myopathies, enabling doctors to build a complementary research portfolio for patients having other rare disorders, including its program for the treatment of hereditary spastic paraplegias caused by mutations in the gene.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 850, Boulevard Sébastien Brant
  • 67400
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 850, Boulevard Sébastien Brant
  • 67400
  • France

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dynacure Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 02-Mar-2023 Completed Generating Revenue
7. IPO 25-Jun-2021 Cancelled Clinical Trials - Phase 1
6. Later Stage VC (Series C) 05-Nov-2020 Completed Clinical Trials - General
5. Grant 25-Apr-2019 Completed Clinical Trials - General
4. Early Stage VC 06-Jul-2018 Completed Clinical Trials - General
3. Early Stage VC 10-Nov-2017 Completed Clinical Trials - General
2. Early Stage VC 01-Nov-2016 $3.6M $4.03M Completed Clinical Trials - General
1. Accelerator/Incubator 01-Oct-2016 $425K $425K Completed Clinical Trials - General
To view Dynacure’s complete valuation and funding history, request access »

Dynacure Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C Shares
B Shares
Series A 491,260 $0.117608 $18.82 $18.82 1x $18.82 9.87%
Ordinary 272,550 $0.117608 $14.11 $14.11 1x $14.11 5.47%
To view Dynacure’s complete cap table history, request access »

Dynacure Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage drug development company created to improve the lives of patients with rare and orphan dise
Drug Discovery
France
29 As of 2022

San Diego, CA
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dynacure Competitors (6)

One of Dynacure’s 6 competitors is Avidity Biosciences, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avidity Biosciences Formerly VC-backed San Diego, CA
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Dyne Therapeutics Formerly VC-backed Waltham, MA
Arrowhead Pharmaceuticals Corporation Pasadena, CA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
To view Dynacure’s complete competitors history, request access »

Dynacure Patents

Dynacure Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4311546-A1 Combination therapy for myopathies Pending 26-Jul-2022
EP-4215614-A1 Combination therapy for dystrophin-related diseases Inactive 24-Jan-2022

Dynacure Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dynacure Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andera Partners PE/Buyout Minority
Bpifrance Sovereign Wealth Fund Minority
Conectus Accelerator/Incubator Minority
Government of France Government
Idinvest Partners PE/Buyout Minority
You’re viewing 5 of 11 investors. Get the full list »

Dynacure FAQs

  • When was Dynacure founded?

    Dynacure was founded in 2015.

  • Where is Dynacure headquartered?

    Dynacure is headquartered in France.

  • What is the size of Dynacure?

    Dynacure has 29 total employees.

  • What industry is Dynacure in?

    Dynacure’s primary industry is Drug Discovery.

  • Is Dynacure a private or public company?

    Dynacure is a Private company.

  • What is Dynacure’s current revenue?

    The current revenue for Dynacure is .

  • How much funding has Dynacure raised over time?

    Dynacure has raised $126M.

  • Who are Dynacure’s investors?

    Andera Partners, Bpifrance, Conectus, Government of France, and Idinvest Partners are 5 of 11 investors who have invested in Dynacure.

  • Who are Dynacure’s competitors?

    Avidity Biosciences, Dicerna Pharmaceuticals, Dyne Therapeutics, Arrowhead Pharmaceuticals, and Sarepta Therapeutics are some of the 6 competitors of Dynacure.

  • When was Dynacure acquired?

    Dynacure was acquired on 02-Mar-2023.

  • Who acquired Dynacure?

    Dynacure was acquired by Flamingo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »